Table 6 Distribution of Patients by Country
Previous Treatment in Main Study | |||
|---|---|---|---|
Total Group | Ovaleap® | Gonal-f® | |
Cycle 2 | N = 147 | N = 80 | N = 67 |
n (%) | n (%) | ||
Belgium + Germany | 24 (16.3) | 11 (13.8) | 13 (19.4) |
Czech Republic | 28 (19.0) | 16 (20.0) | 12 (17.9) |
Hungary | 39 (26.5) | 22 (27.5) | 17 (25.4) |
Poland | 56 (38.1) | 31 (38.8) | 25 (37.3) |
Cycle 3 | N = 61 | N = 34 | N = 27 |
n (%) | n (%) | ||
Belgium + Germany | 3 (4.9) | 1 (2.9) | 2 (7.4) |
Czech Republic | 8 (13.1) | 6 (17.6) | 2 (7.4) |
Hungary | 20 (32.8) | 12 (35.3) | 8 (29.6) |
Poland | 30 (49.2) | 15 (44.1) | 15 (55.6) |